Grass Pollen Allergy (Immunology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy – Drugs In Development, 2021, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 2, 6 and 1 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).

– The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

DC4U BV

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Roxall Medizin GmbH

Worg Pharmaceuticals Hangzhou Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Grass Pollen Allergy - Overview

Grass Pollen Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Grass Pollen Allergy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Grass Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

ASIT Biotech SA

DC4U BV

HAL Allergy BV

Regeneron Pharmaceuticals Inc

Roxall Medizin GmbH

Worg Pharmaceuticals Hangzhou Co Ltd

Grass Pollen Allergy - Drug Profiles

Allergen for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dupilumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gp-ASIT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Quattro Grass - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Grass Pollen Allergy and House Dust Mite Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WP-1048 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Grass Pollen Allergy - Dormant Projects

Grass Pollen Allergy - Discontinued Products

Grass Pollen Allergy - Product Development Milestones

Featured News & Press Releases

May 06, 2021: Allergy Therapeutics: Completion of treatment phase in G309 study

Aug 26, 2020: Chronic hepatitis B: vaccine against grass pollen allergy as potential treatment

Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme

Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial

Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update

Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy

May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study

Feb 05, 2018: Landmark clinical study with grass pollen vaccine BM32 published

Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32

Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B

Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204

Jun 13, 2016: New Data From GAP Landmark Trial Confirm GRAZAX Prevents Asthma Symptoms in Children

Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study

Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL

Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Grass Pollen Allergy, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Grass Pollen Allergy – Pipeline by ALK-Abello AS, 2021

Grass Pollen Allergy – Pipeline by Allergy Therapeutics Plc, 2021

Grass Pollen Allergy – Pipeline by ASIT Biotech SA, 2021

Grass Pollen Allergy – Pipeline by DC4U BV, 2021

Grass Pollen Allergy – Pipeline by HAL Allergy BV, 2021

Grass Pollen Allergy – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Grass Pollen Allergy – Pipeline by Roxall Medizin GmbH, 2021

Grass Pollen Allergy – Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2021

Grass Pollen Allergy – Dormant Projects, 2021

Grass Pollen Allergy – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Grass Pollen Allergy, 2021

Number of Products under Development by Companies, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports